A Case of High Dose Cytosine Arabinoside Induced Stevens-Johnson Syndrome in a Patient with Malignant Lymphoma.
10.5045/kjh.2007.42.3.292
- Author:
Ji Won AN
1
;
Myung Ah LEE
;
Yoon Ho KO
;
Sung Min NAM
;
Mun Kyung CHUNG
;
Su Jin MOON
;
Jin Hyoung KANG
;
Young Seon HONG
;
Kyung Shik LEE
Author Information
1. Division of Oncology, Department of Internal Medicine, Catholic University Medical College, Seoul, Korea. y331@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Stevens-Johnson syndrome;
Cytosine arabinoside;
Lymphoma
- MeSH:
Adolescent;
Aged;
Cytarabine*;
Cytosine*;
Female;
Humans;
Korea;
Lymphoma*;
Lymphoma, Mantle-Cell;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Stevens-Johnson Syndrome*
- From:Korean Journal of Hematology
2007;42(3):292-295
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Many chemotherapeutic agents induce variable cutaneous adverse reactions. Among the side effects, Stevens-Johnson syndrome is rare, but a fatal complication. There are two prior reports of cytosine arabinoside (ARA-C) induced toxic epidermal necrolysis, which is considered in the continuum of Stevens- Johnson syndrome. The prior cases were female patients under 16 years old with acute lymphocytic leukemia. We treated a 77-year-old man with recurrent mantle cell lymphoma who developed Stevens- Johnson syndrome after high dose ARA-C therapy. This is the first case of ARA-C induced Stevens- Johnson syndrome in Korea.
